abs234.txt	introduction		muscle	wasting	has	detrimental	effects	including	increasedmortality	identifying	patients	at	risk	can	guide	treatment	efforts	methods	power	1	and	2	were	randomized	double-blind	placebo-controlled	multinational	phase	iii	trials	that	studied	600	with	lung	cancer	thestart	of	chemotherapy	the	studies'	aim	was	to	assess	efficacy	enobosarmon	prevention	loss	we	performed	a	secondary	analysisrestricted	control	group	using	cumulative	logit	model	for	ordinaloutcome	determine	which	baseline	characteristics	predicted	physical	andfunctional	during	results	in	all	53%	had	lean	body	mass	49%	ofstair	climb	(scp)	day	84	322	who	receivedplacebo	232	observable	outcome	covariates	included	forlean	analysis	236	scp	more	advanced	disease	predicteda	higher	probability	greater	(or	=	96	95%	confidence	interval[ci]	14-3	36)	three	factors	taxanechemotherapy	73	ci	06-2	83)	tobacco	use	before	chemotherapy(or	15	10-4	18)	01	004-1	015)	index	protective	factor	functional	loss(or	0	85	73-0	98)	eastern	cooperative	oncology	groupperformance	status	trended	toward	being	predictive	bothphysical	(0	767)	070)	but	notstatistically	significant	conclusions	approximately	50%	wereundergoing	ongoing	function	stage	taxane	chemotherapypredicted	functionalloss	identified	predictors	could	be	usedas	therapeutic	targets	or
